Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with β-thalassemia major

International Journal of Hematology

Volumn 86, Issue 5, 2007, Pages 385-389

  Perifanis, Vassilios ^a   Christoforidis, Athanasios ^a,c   Vlachaki, Efthimia ^a   Tsatra, Ioanna ^a   Spanos, George ^b   Athanassiou Metaxa, Miranda ^a  

^a Ippokration Hospital Thessaloniki   (Greece)

^b Diagnostic Laboratory Eurodiagnosis   (Greece)

^c Aristotle University of Thessaloniki   (Greece)

Author keywords

thalassemia; Deferiprone; Deferoxamine; Iron chelation; Magnetic resonance imaging; T2*

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; IRON CHELATING AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; COMBINATION CHEMOTHERAPY; CORONARY RISK; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; FEMALE; FERRITIN BLOOD LEVEL; HEART; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; IRON STORAGE; LIVER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; DEFEROXAMINE; FEMALE; FERRITINS; HEART VENTRICLES; HUMANS; IRON; LIVER; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MONITORING, PHYSIOLOGIC; MYOCARDIUM; ORGAN SIZE; PYRIDONES; SIDEROPHORES; TIME FACTORS;

EID: 38349075317     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.E0734     Document Type: Article

References (33)

1. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci. 2005;1054:40-47.
2. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, and the Thalassemia Clinical Research Network. Complications of β-thalassemia major in North America. Blood. 2004;104:34-39.
3. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489-496.
4. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106:3242-3250.
5. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001;138:130-138.
6. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361-364.
7. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187-189.
8. Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica. 2005;90:1309-1314.
9. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85:315-319.
10. Johnston DL, Rice L, Vick GW 3rd, Hedrick TD, Rokey R. Assessment of tissue iron overload by nuclear magnetic resonance imaging. Am J Med. 1989;87:40-47.
11. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood. 2003;101:15-19.
12. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-2179.
13. Bellenger NG, Francis JM, Davies CL, Coats AJ, Pennell DJ. Establishment and performance of a magnetic resonance cardiac function clinic. J Cardiovasc Magn Reson. 2000;2:15-22.
14. Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP Jr. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson. 1999;1:7-21.
15. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology Am Soc Hematol Educ Program. 2004:14-34.
16. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106:1460-1465.
17. Jensen PD. Evaluation of iron overload. Br J Haematol. 2004;124:697-711.
18. Gossuin Y, Roch A, Muller RN, Gillis P. Relaxation induced by ferritin and ferritin-like magnetic particles: the role of proton exchange. Magn Reson Med. 2000;43:237-243.
19. Bonkovsky HL, Rubin RB, Cable EE, Davidoff A, Rijcken TH, Stark DD. Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. Radiology. 1999;212:227-234.
20. Perifanis V, Economou M, Christoforides A, Koussi A, Tsitourides I, Athanassiou-Metaxa M. Evaluation of iron overload in beta-thalassemia patients using magnetic resonance imaging. Hemoglobin. 2004;28:45-49.
21. Christoforidis A, Haritandi A, Tsitouridis I, et al. Correlative study of iron accumulation in liver, myocardium, and pituitary assessed with MRI in young thalassemic patients. J Pediatr Hematol Oncol. 2006;28:311-315.
22. Westwood MA, Anderson LJ, Firmin DN, et al. Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging. 2003;18:616-620.
23. Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ, on behalf of the Thalassemia International Federation Heart T2* Investigators. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica. 2006;91:1388-1391.
24. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet. 2002;360:516-520.
25. Pepe A, Lombardi M, Positano V, et al. Evaluation of the efficacy of oral deferiprone in β-thalassemia major by multislice multiecho T2*. Eur J Haematol. 2006;76:183-192.
26. Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol. 2003;70:392-397.
27. Shalev O, Repka T, Goldfarb A, et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood. 1995;86:2008-2013.
28. de Franceschi L, Shalev O, Piga A, et al. Deferiprone therapy in homozygous human β-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. J Lab Clin Med. 1999;133:64-69.
29. Porter JB. Development of Primary Hepatocyte Cultures for the Preclinical Evaluation of Iron Chelators [MD thesis]. Cambridge, UK: University of Cambridge; 1999.
30. Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with β-thalassaemia major: comparison between different chelation regimens. Eur J Haematol. 2007;78:52-57.
31. Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis. 2006;36:21-25.
32. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia: the protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30:239-249.
33. Tanner MA, Galanello R, Dessi C, et al. The effect of combined therapy with deferoxamine and deferiprone on myocardial iron and endothelial function in thalassemia major: a randomized controlled trial using cardiovascular magnetic resonance [abstract]. Haematologica. 2006;91(suppl 1). Abstract 0517.